Brain Ischemia - Pipeline Review, H2 2016

  • ID: 3946410
  • Drug Pipelines
  • 58 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CohBar, Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Sylentis S.A.U.
  • Vect-Horus S.A.S.
  • MORE
Brain Ischemia - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Brain Ischemia - Pipeline Review, H2 2016, provides an overview of the Brain Ischemia (Central Nervous System) pipeline landscape.

Brain ischemia is a stroke is when the blood supply to any part of the brain is interrupted, resulting in tissue death and loss of brain function. The most common cause of stroke is atherosclerosis. Symptoms include loss of movement of body area, weakness, numbness, decreased vision, loss of memory, vertigo, loss of coordination and urinary incontinence. Treatment includes analgesics to control severe headache, anti-hypertensive medication to control high blood pressure and anti-platelet agents.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Brain Ischemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Ischemia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 9 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively for Brain Ischemia.

Brain Ischemia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Ischemia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Brain Ischemia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Brain Ischemia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Brain Ischemia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Brain Ischemia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Brain Ischemia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Brain Ischemia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CohBar, Inc.
  • NeuroNascent, Inc.
  • NeurOp, Inc
  • Sylentis S.A.U.
  • Vect-Horus S.A.S.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Brain Ischemia Overview

Therapeutics Development

Pipeline Products for Brain Ischemia - Overview

Pipeline Products for Brain Ischemia - Comparative Analysis

Brain Ischemia - Therapeutics under Development by Companies

Brain Ischemia - Therapeutics under Investigation by Universities/Institutes

Brain Ischemia - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Brain Ischemia - Products under Development by Companies

Brain Ischemia - Products under Investigation by Universities/Institutes

Brain Ischemia - Companies Involved in Therapeutics Development

CohBar, Inc.

Lixte Biotechnology Holdings, Inc.

NeuroNascent, Inc.

NeurOp, Inc

Prolong Pharmaceuticals, LLC

Spectrum Pharmaceuticals, Inc.

Sylentis S.A.U.

Vect-Horus S.A.S.

Brain Ischemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

2-CCPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADA-409 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Humanin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAU-0901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-10679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phycocyanobilin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sanguinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPI-1620 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VHN-439 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Brain Ischemia - Dormant Projects

Brain Ischemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Brain Ischemia, H2 2016

Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Brain Ischemia - Pipeline by CohBar, Inc., H2 2016

Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016

Brain Ischemia - Pipeline by NeuroNascent, Inc., H2 2016

Brain Ischemia - Pipeline by NeurOp, Inc, H2 2016

Brain Ischemia - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016

Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016

Brain Ischemia - Pipeline by Sylentis S.A.U., H2 2016

Brain Ischemia - Pipeline by Vect-Horus S.A.S., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Brain Ischemia - Dormant Projects, H2 2016

Brain Ischemia - Dormant Projects (Contd..1), H2 2016

Brain Ischemia - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Brain Ischemia, H2 2016

Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
CohBar, Inc.
Lixte Biotechnology Holdings, Inc.
NeuroNascent, Inc.
NeurOp, Inc
Prolong Pharmaceuticals, LLC
Spectrum Pharmaceuticals, Inc.
Sylentis S.A.U.
Vect-Horus S.A.S.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll